Bionomics (BNOX)
(Delayed Data from NSDQ)
$0.83 USD
+0.07 (8.85%)
Updated Jul 16, 2024 03:59 PM ET
After-Market: $0.83 0.00 (-0.57%) 6:40 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Brokerage Reports
Bionomics Limited Unsponsored ADR [BNOX]
Reports for Purchase
Showing records 1 - 15 ( 15 total )
Company: Bionomics Limited Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Important Overhang Addressed; Phase 3 SAD Study to Start Shortly; PTSD Up Next
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Bionomics Limited Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Compelling Full ATTUNE PTSD Results Forge Pivotal Path Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Bionomics Limited Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Pipeline Update Provides Detailed Roadmap For BNC210''s Path; We See BD as Big Component
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Bionomics Limited Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Psychometric Analysis Confirms SUDS Reliability in Anxiety Assessment; Phase 3 SAD Program Launches 1Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Bionomics Limited Unsponsored ADR
Industry: Medical - Biomedical and Genetics
An Important Handshake We''ve Been Anticipating; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Bionomics Limited Unsponsored ADR
Industry: Medical - Biomedical and Genetics
BNC210 Should Be First in Pivotal SAD Study as Comp Shares Plans; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Bionomics Limited Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Phoenix Rises With Core Data Foundations; PTSD Phase 2b Win; Upgrade to Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Bionomics Limited Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Nothing to be SAD About; PALISADE-2 Data Underscore BNC210''s Potential
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Bionomics Limited Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Final PREVAIL SAD Data Point in Right Direction; EOP2 Meeting Planned for 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Bionomics Limited Unsponsored ADR
Industry: Medical - Biomedical and Genetics
We Are SAD To Move To Sidelines; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Bionomics Limited Unsponsored ADR
Industry: Medical - Biomedical and Genetics
BNC210 Close to Burst Into Speech; PREVAIL Top-Line Data in SAD by YE22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Bionomics Limited Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Time to Step Up for These Catalysts; Making Real Differences
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Bionomics Limited Unsponsored ADR
Industry: Medical - Biomedical and Genetics
BNC210 Remains Differentiated, In Our Belief; PREVAIL Data Readout Expected by Year End
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Bionomics Limited Unsponsored ADR
Industry: Medical - Biomedical and Genetics
F1H22 Results; We Are Happy About the SAD Data Later This Year; PTSD Data Soon After; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Bionomics Limited Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Welcome to the U.S.; Continuing Our Coverage With BNC210 Excitement; ADS Target to $54
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
|